So far we are still waiting on information to see if they remain virus free after treatment ends. The first group has yet to complete the year long course of treatment but I think it is coming up soon. They took VX950 but then continued the standard course with Interferon and Riba for the 48 weeks. The participants did show a high rate of clearing the virus with VX950. They were also on Interferon and taking Riba, we don't know if they will remain virus free after treatment ends or not yet. Let's hope so.
Agree with the above post - nobody knows yet.
Just like many other very promising drugs that have come and gone - there is no given with this one yet but we are all praying big time for it.
Sorry - no odds yet but it does appear to kill the virus very quickly and lead to UND fast. will that hold on SVR is anybody's guess - or is the Interferon and Riba they also take the thing that is working.
I can't wait to find out.
So far, in an early 1b trial where 950 was dosed for 2 weeks with IFN, and then IFN and riba was followed on for 22 weeks and stopped, 5 out of 6 people remain undetectable 12 weeks after stopping tx. They were all geno 1's who treated a total of 24 weeks.
In another arm, one treated for 28 days with 950, IFN, and riba, and then followed on for 14 more weeks (18 total) with IFN and riba before deciding to stop on their own, and they remain undetectable at this point. That is a geno 1 who treated a total of 18 weeks.
There is no 6 month SVR data out yet. The 3 month data in those small arms is good so far, as it usually relapses by then. They are testing to <10 copies throughout.
This is new data, just released last week. Data including more people with 3 month prelim SVR isn't due until late first quarter next year.
i appreciate everyones feedback. I had one other question regarding current treatment options. Do you think the peg interferon or the interfergon is more effective with the riba? just considerring options before addressing with an md.Thanks
There is a lot of information to gather about your condition before you can make a decision on which treatment approach to take. What genotype are you?
The early 950 trials produced promising indications, but little more than that. The sample sizes were too small to be statistically significant. Vertex acknowledged this during their investor conference this past week.
That said, there is currently a 260 subject trial underway for treatment naive geno 1 with stage 2 + liver damage by bx. The trial subject will start to be unblinded over the next couple of months, and will then know their VL profile since starting the trial. The expectation is rapid viral response to UND in times that could be less than a month [just a guess].
As these subjects are followed through 2007, we should see some reliable efficacy numbers published.